CARLSBAD, Calif.–(BUSINESS WIRE)–Rapalogix Health, a biotechnology company advancing a science-first approach to cellular longevity and skin health, today announced the closing of a $20 million Series A financing co-led by GordonMD Global Investments® LP (“GordonMD”) — the Beverly Hills-based physician-led biopharma investment firm — and Woodline Partners. The round reflects GordonMD’s conviction that mechanism-driven platforms in dermatology represent a compelling and underserved frontier in
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
